Integrin receptor-targeted, doxorubicin-loaded cerium oxide nanoparticles delivery to combat glioblastoma.
Gayathri KoulaVenu YakatiHari Krishnareddy RachamallaKeerti BhamidipatiMuralidharan KathirvelRajkumar BanerjeeNagaprasad PuvvadaPublished in: Nanomedicine (London, England) (2024)
Aim: To assess the chemo-immunomodulatory effects of doxorubicin-loaded cerium oxide nanoparticles coated with oleyl amine-linked cyclic RGDfK peptide (CeNP+Dox+RGD) to target both gliomas and its tumor microenvironment (TME) via integrin receptors. Materials & methods: CeNP+Dox+RGD nanoparticles are synthesized by the sequential addition of cerium III chloride heptahydrate, beta-cyclodextrin, oleic acid, and F127 micelle (CeNP). Doxorubicin was then loaded into CeNPs and coated with oleyl amine-linked cyclic RGDfK peptide to form stable CeNP+Dox+RGD nanoparticles. Results: CeNP+Dox+RGD nanoparticles crossed blood-brain barrier (BBB) effectively and demonstrated threefold enhanced survivability in glioma-bearing mice. The IHC profiling of glial tumor cross-sections showed increased CD80 expression (M1 TAMs) and decreased arginase-1 expression (M2 TAMs). Conclusion: CeNP+Dox+RGD can be an immunotherapeutic treatment option to combat glioblastoma.
Keyphrases
- oxide nanoparticles
- cancer therapy
- blood brain barrier
- drug delivery
- poor prognosis
- cerebral ischemia
- binding protein
- squamous cell carcinoma
- combination therapy
- wound healing
- neuropathic pain
- photodynamic therapy
- skeletal muscle
- long non coding rna
- radiation therapy
- cell adhesion
- single cell
- walled carbon nanotubes
- metabolic syndrome
- brain injury
- replacement therapy
- locally advanced
- smoking cessation
- rectal cancer